

RECEIVED
CENTRAL FAX CENTER

MAY 18 2006

MGENE.016A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Lebron, Stewart J.
Appl. No. : 10/719,770
Filed : November 21, 2003
For : MICROARRAY-BASED
ANALYSIS OF RHEUMATOID
ARTHRITIS MARKERS
Examiner : Nelson C. Yang
Group Art Unit: 1641

CERTIFICATE OF FAX TRANSMISSION

I hereby certify that this correspondence and all
marked attachments are being facsimile
transmitted to the Office of Initial Patent
Examination Customer Service Center at 571-
273-8300 at the U.S. Patent and Trademark
Office on the date shown below:

May 18, 2006

(Date)


Eric Lee, Reg. No. 50,928REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Office of Initial Patent Examination
Customer Service Center
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that the Official Filing Receipt, a copy of which is enclosed, be corrected to reflect the following: please add U.S. Serial No. 60/417,068 filed 10/08/02 to the DOMESTIC PRIORITY DATA AS CLAIMS BY APPLICANT section. For your convenience, a copy of the Declaration/Power of Attorney and cover page of the specification is enclosed.

Appl. No. : 10/719,770
Filed : November 21, 2003

We look forward to receiving the corrected filing receipt in due course.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 5-18-2006

By: 

Eric Ives
Registration No. 50,928
Agent of Record
Customer No. 20,995
(805) 547-5580

2604239-vr
051606

MGENE.016A₆₂ Page 1 of 3
 MBB FBI



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

| APPL NO. | FILING OR 371 (3) DATE | ART UNIT | FIL FEE REC'D | ATTY DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|------------------------|----------|---------------|----------------|----------|----------|----------|
| 10/719,770 | 11/21/2003 | 1641 | 493 | MGENE.016A | 14 | 20 | 4 |

CONFIRMATION NO. 3300

UPDATED FILING RECEIPT



OC00000018213639

20995
 KNOBBE MARTENS OLSON & BEAR LLP
 2040 MAIN STREET
 FOURTEENTH FLOOR
 IRVINE, CA 92614

Date Mailed: 03/07/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stewart J. Lebrun, Irvine, CA;

Power of Attorney: The patent practitioners associated with Customer Number 20995.

Domestic Priority data as claimed by applicant

this application claims benefit of 60/417,068 10/08/02

Foreign Applications

If Required, Foreign Filing License Granted: 04/05/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10719,770

Projected Publication Date: 06/15/2006

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Microarray-based analysis of rheumatoid arthritis markers

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER**Title 35, United States Code, Section 184****Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR

1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12. If a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Page 1

Attorney's Docket No. MGENE.016A

DECLARATION - USA PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled MICROARRAY-BASED ANALYSIS OF RHEUMATOID ARTHRITIS MARKERS; the specification of which was filed on November 21, 2003 as Application Serial No. 10/719,770.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;


I hereby claim the benefit under Title 35, United States Codes § 119(e) of any United States provisional application(s) listed below.

Application No.: 60/417,068

Filing Date: October 8, 2002

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole inventor: Stewart J. Lebrun

Inventor's signature: 

Date: July 6 04

Residence: 386 Santa Louisa, Irvine, CA 92606

Citizenship: United States

Mailing Address: Box 4177, Irvine, CA 92616

Send Correspondence To:
KNOBBE, MARTENS, OLSON & BEAR, LLP
Customer No. 20995

F:\DOCS\CSC\CSC-714.DOC\60204

MGENE.016A

PATENT

MICROARRAY-BASED ANALYSIS OF RHEUMATOID ARTHRITIS MARKERSBackground of the InventionRelated Applications

[0001] Related provisional application no. 60/417,068, filed October 8, 2002, is incorporated herein by reference.

Field of the Invention

[0002] In one embodiment, the disclosed invention relates to a microarray with markers for rheumatoid arthritis and a method for detection of rheumatoid arthritis. In another embodiment, the invention relates to treatment for the disease.

Description of the Related Art

[0003] Rheumatoid arthritis (RA) is a chronic systemic disorder that affects joints and surrounding tissues as well as other organ systems. The cause is unknown. Infections, genetic and hormonal factors have been suggested. RA eventually effects the ability to perform daily activities and overall quality of life.

[0004] RA effects both sides of the body equally, most commonly wrists, fingers, knees, feet and ankles. When the synovium (joint lining) is affected, the synovium becomes inflamed, secretes more fluid and the joint becomes swollen. Later, the cartilage becomes rough and pitted and the underlying bone becomes affected. Joint destruction typically begins 1-2 years after the appearance of the disease. Organs may also be affected, particularly the lungs, heart and vascular system.

[0005] There is no cure for RA although intervention can delay onset of symptoms. Consequently, an early marker for the disease would be useful to provide an early diagnosis. A rheumatoid factor test is available. However, this test is positive in only about 75% of people with symptoms.

[0006] Recent technological advances enable high throughput screening of proteins. These include the sequencing of the human genome and the development of high throughput, robotic screening methods required to handle the numbers of samples involved in